Wells Fargo & Company MN Has $11.44 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wells Fargo & Company MN decreased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 11.7% in the fourth quarter, Holdings Channel reports. The fund owned 863,678 shares of the company’s stock after selling 114,324 shares during the period. Wells Fargo & Company MN’s holdings in Takeda Pharmaceutical were worth $11,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth about $26,000. Wilmington Savings Fund Society FSB bought a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets increased its position in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after buying an additional 2,596 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares during the period. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth $52,000. 9.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 1.7 %

NYSE TAK opened at $14.55 on Wednesday. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The stock has a market cap of $46.28 billion, a PE ratio of 36.36, a PEG ratio of 0.24 and a beta of 0.39. The firm has a 50-day simple moving average of $14.50 and a 200 day simple moving average of $13.90. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.